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Background: Acute myeloid leukemia (AML) remains a difficult disease to treat and requires new therapies to
improve treatment outcome. Wee1 inhibitors have been used to prevent activation of the G2 cell cycle checkpoint,
thus enhancing the antitumor activity of DNA damaging agents. In this study, we investigated MK-1775 in AML cell
lines and diagnostic blast samples to identify sensitive subtypes as well as possible mechanisms of resistance.
Methods: In vitro MK-1775 cytotoxicities of AML cell lines and diagnostic blasts were measured using MTT assays.
The effects of MK-1775 on cell cycle progression and related proteins were determined by propidium iodide (PI)
staining and flow cytometry analysis and Western blotting. Drug-induced apoptosis was determined using annexin
V/PI staining and flow cytometry analysis.
Results: We found that newly diagnosed and relapsed patient samples were equally sensitive to MK-1775. In
addition, patient samples harboring t(15;17) translocation were significantly more sensitive to MK-1775 than
non-t(15;17) samples. MK-1775 induced apoptosis in both AML cell lines and diagnostic blast samples, accompanied
by decreased phosphorylation of CDK1 and CDK2 on Tyr-15 and increased DNA double-strand breaks (DSBs).
Time-course experiments, using AML cell lines, revealed a time-dependent increase in DNA DSBs, activation of
CHK1 and subsequent apoptosis following MK-1775 treatment, which could be attenuated by a CDK1/2 inhibitor,
Roscovitine. Simultaneous inhibition of CHK1 and Wee1 resulted in synergistic anti-leukemic activity in both AML
cell lines and primary patient samples ex vivo.
Conclusions: Our study provides compelling evidence that CHK1 plays a critical role in the anti-leukemic activity of
MK-1775 and highlights a possible mechanism of resistance to MK-1775. In addition, our study strongly supports
the use of MK-1775 to treat both newly diagnosed and relapsed AML, especially cases with t(15;17) translocation,
and supports the development of combination therapies with CHK1 inhibitors.
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Acute myeloid leukemia (AML) is a challenging disease to
treat, with overall survival rates of 65% for children and
25% for adults [1,2]. Resistance to cytarabine (ara-C) and
anthracycline [e.g. daunorubicin (DNR)]-based chemother-
apy remains a major cause of treatment failure. Therefore,
new therapies are greatly needed to treat this disease.
One mechanism of chemotherapy resistance is the in-
duction of G2/M cell cycle arrest, which allows cells to
repair and survive DNA damage [3]. Wee1 kinase is a
cell cycle checkpoint protein whose primary function is
inhibitory phosphorylation of CDK1 and CDK2 on Tyr-
15, preventing progression through G2/M and S phase,
respectively [4,5]. Inhibitory phosphorylation of CDK1
and CDK2 on Tyr-15 is removed by CDC25 phospha-
tases [6,7]. CDC25 activity is inhibited when phosphory-
lated by CHK1, which is in turn controlled primarily by
ATR kinase [8,9]. Upon sensing DNA damage or replica-
tion stress ATR phosphorylates CHK1, activating it and
eventually leading to S and G2 cell cycle arrest, allowing
for DNA repair [8,9].
The first selective and potent Wee1 inhibitor, MK-1775,
has been primarily used to target the G2 checkpoint to
exert toxicity in cells with impaired p53 function [10]. It
has been demonstrated that when combined with DNA
damaging agents it is able to abrogate the G2 checkpoint
and enhance apoptosis [10-18]. In addition, Wee1 inhib-
ition has been shown to induce DNA damage through the
induction of replication stress secondary to overactive
CDKs and inhibition of DNA repair [19].
In this study, we used AML cell lines and blast samples
obtained either at diagnosis or at relapse to investigate the
cytotoxic effects of MK-1775 on AML. Our results suggest
that MK-1775 may be equally effective in newly diagnosed
and relapsed AML. Additionally, we demonstrate that
patient samples harboring t(15;17) translocation are sig-
nificantly more sensitive to MK-1775 than others. Further-
more, our study suggests that MK-1775 treatment induces
DNA damage which activates CHK1, CHK1 phosphory-
lates CDC25, inhibiting the dephosphorylation of CDK1/
2, thus countering the effects of MK-1775. Activation of
CHK1 can be overcome by the addition of a CHK1 inhibi-
tor, resulting in synergistic anti-leukemic activity. This
demonstrates a potential mechanism of resistance to MK-
1775 treatment and highlights the importance of combin-
ation therapies.
Results
MK-1775 induces DNA damage and apoptosis in AML cells
To investigate the effects of MK-1775 in AML cells, first
we determined the protein levels of Wee1, p-CDK1,
CDK1, p-CDK2, CDK2 and MYT1 in six AML cell lines.
The proteins were expressed at variable levels (Figure 1A).
Next, we tested drug sensitivity by MTT assays. The IC50sranged from about 200-400 nM after 72 h treatment
(Figure 1B). To determine if MK-1775 induces cell death,
we treated the cell lines with up to 500 nM MK-1775 for
48 h and assessed viability using the trypan blue exclusion
assay. As shown in Figure 1C, there was a concentration-
dependent increase in dead cells for all six cell lines tested.
Annexin V/PI staining and flow cytometry analysis re-
vealed that MK-1775 caused concentration-dependent
increase in apoptotic cells (Figure 1D). This was accom-
panied by decreased p-CDK1 and p-CDK2 and in-
creased total CDK1 and CDK2 (Figure 1E). There was
also a concentration-dependent increase of phosphory-
lated H2AX (γH2AX), indicating increased DNA double-
strand breaks (DSBs) [γH2AX is an established biomarker
for DNA DSBs [20]]. The CTS and U937 cell lines were
chosen as representative AML cell lines for further mech-
anistic studies.
Next, we determined ex vivo MK-1775 sensitivity in
freshly isolated AML blast samples (n = 29). MK-1775
IC50s ranged from 217 nM (AML#16) to 6.4 μM
(AML#27, Table 1). Similar to the cell lines, we detected
a concentration-dependent increase in apoptosis for three
patient samples after MK-1775 treatment (Figure 2A).
Interestingly, the median MK-1775 IC50 for the diagnostic
(n = 23) and relapse samples (n = 6) were similar (1176
and 896.1 nM, respectively, p = 0.936, Figure 2B). In
addition, we found that patient samples harboring t(15;17)
translocation (n = 5) were significantly more sensitive to
MK-1775 than non-t(15;17) samples (n = 24, p = 0.007,
Figure 2C). Next, we generated a cytarabine resistant cell
line (HL60/Ara-C) to determine if they would exhibit
cross-resistance to MK-1775. Despite being approximately
600-times more resistant to cytarabine than the parental
HL-60 cells (Figure 2D), HL-60/Ara-C cells were more
sensitive to MK-1775 treatment (Figure 2E). There was a
concentration-dependent increase in apoptotic cells for
the HL60/Ara-C cell line, whereas the parental cell line
remained relatively unaffected by MK-1775 concentra-
tions up to 500 nM. A concentration-dependent decrease
in p-CDK1 and p-CDK2 accompanied by increase of
γH2AX was detected in cells from patient AML#10 as
well as in HL60/Ara-C (Figure 2F). HL60 cells treated
with 500 nM MK-1775 had a small increase of γH2AX
and no change in p-CDK1 or p-CDK2, probably due to
very low levels of expression prior to drug treatment.
Next, we investigated the effects of MK-1775 on cell
cycle progression in both CTS and U937 cells. Treat-
ment with MK-1775 for 48 h revealed a concentration-
dependent decrease of the G2/M population accompan-
ied by concentration-dependent increase of the sub-G1
population (Additional file 1: Figure S1). Time course
experiments revealed a time-dependent increase of the
sub-G1 population and abrogation of the G2 checkpoint
for both cell lines (Figure 3A&C and Additional file 2:
Figure 1 MK-1775 induces apoptosis in AML cells. Panel A: Protein extracts from 6 AML cell lines were subjected to Western blotting and
probed with anti-Wee1, -Myt1, -p-CDK1 (Y15), -CDK1, -p-CDK2 (Y15), -CDK2, or -β-actin antibody. Panel B: AML cell lines were cultured for 72 h in
complete medium with variable concentrations of MK-1775 (MK) and viable cell numbers were determined using MTT assays. IC50 values were
calculated as drug concentration necessary to inhibit 50% growth compared to untreated control cells. The data for panels B and C are presented
as mean values ± standard errors from at least 3 independent experiments. Panel C-E: AML cells were treated with MK-1775 for 48 h. The
percentage of dead cells was determined by Trypan blue exclusion (Panel C). Apoptotic events were determined by annexin V/PI staining and
flow cytometry analyses (Panel D). The data for panel D are presented as mean values ± standard errors of triplicates from one representative
experiment which was repeated 3 independent times. Whole cell lysates were subjected to Western blotting, and probed with anti-p-CDK1,
-CDK1, -p-CDK2, -CDK2, -γH2AX, or -β-actin antibody (Panel E). Representative Western blots are shown.
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dependent increase of γH2AX as well as a decrease of
p-CDK1 and p-CDK2 (Figure 3B&D). Increased total
CDK1 levels were detected following MK-1775 treat-
ment. Increased p-CHK1 was detected as early as 4 h
following MK-1775 treatment.
CDK activity is required for MK-1775 anti-leukemic
activity
To determine if CDK activity is required for MK-1775
induced DNA damage and apoptosis, we treated AML
cells with Roscovitine, a CDK inhibitor. There was a
concentration-dependent decrease in viable cells after
Roscovitine treatment for both CTS and U937 cells, asmeasured by MTT assays (Additional file 1: Figure S2A).
Increased γH2AX and p-CHK1 was observed following
8 h MK-1775 treatment, which was substantially abolished
by the addition of Roscovitine (Figure 4A and Additional
file 1: Figure S3A). MK-1775 induced apoptosis at both
8 h and 24 h in both CTS and U937 cell lines. Combined
MK-1775 and Roscovitine treatment abolished MK-1775
induced apoptosis (Figure 4B&C). MTT assays revealed
clearly antagonistic anti-leukemic interactions as shown
in the standard isobolograms (Figure 4D&E). Similar re-
sults were obtained with primary AML patient samples
(Figure 4F-H). These results demonstrate that CDK ac-
tivity is required for MK-1775 anti-leukemic activity in
AML cells.
Table 1 Patient characteristics and MK-1775 sensitivity for primary AML patient samples








AML#0 Female 13 At diagnosis M2 39.9 79 46, XX, t(8;21)(q22;q22) 5996.5
AML#1 Female 50 At diagnosis M4 22.66 52 46, XX, del(5q), add(12p) 2448.5
AML#2 Male 20 At diagnosis M2 23.55 42 45, X, -Y, t(8;21)(q22;q22) 3204.0
AML#3 Male 4 At diagnosis M3 4.71 75 46, XY, t(15;17)(q22;q21) 461.0
AML#4 Male 55 At relapse M2 5.64 14 46, XY, t(8;21)(q22;q22) 844.0
AML#5 Female 57 At relapse M2 22.16 70 46, XX 948.3
AML#6 Male 60 At diagnosis M3 1.83 86 46, XY, t(15;17)(q22;q21) 233.7
AML#7 Female 53 At relapse M4 3.87 36 46, XX 325.0
AML#8 Male 55 At diagnosis M2 3.87 32 46, XY 887.9
AML#9 Female 35 At relapse M5 17.71 87 47, XX, +10, t(16;21)(p11;q22),
add(11p)
744.4
AML#10 Male 23 At diagnosis M2 25.89 53 46, XY, del(9q) 439.7
AML#11 Female 43 At diagnosis M2 25.12 91 46, XX 411.3
AML#12 Male 6 At diagnosis M3 93.99 85 46, XY, t(15;17)(q22;q21) 277.5
AML#13 Male 52 At diagnosis M2 1.65 27 46, XY, t(11;15;17)(q25;q15;q21) 3579.5
AML#14 Female 18 At diagnosis M3 1.62 64 46, XX 9113
AML#15 Female 63 At diagnosis M2 0.6 23 46, XX 344.1
AML#16 Male 38 At diagnosis M3 2.27 90 46, XY, t(15;17)(q22;q21) 216.9
AML#17 Female 45 At diagnosis M4 1.52 36 46, XX 3473.0
AML#18 Female 19 At relapse M2 21.55 52 46, XX, t(8;21)(q22;q22) 1187.0
AML#19 Male 4 At diagnosis M4 77.32 41 46, XY 5587.0
AML#21 Male 42 At diagnosis M4 10.60 51 46, XY/44, XY, -17, -19, (11q-?) 1176.0
AML#22 Female 47 At diagnosis M5 244.53 80 46, XX 1255.0
AML#23 Male 60 At diagnosis M5 2.10 81 46, XY, +2, +8, I(12)(q10) 1480.0
AML#25 Female 12 At diagnosis M3 5.11 88 46, XX, t(15;17)(q22;q21) 615.1
AML#26 Male 59 At diagnosis M2 129.98 81 46, XY 5868.0
AML#27 Female 41 At relapse M4 40.20 24 47, XX,del(5q),+8,t(15;18)(q12,q23) 6384.0
AML#29 Male 9 At diagnosis M4 68.14 31 46, XY, t(6;9)(p22;q34) 880.4
AML#31 Male 17 At diagnosis M2 12.94 69 46, XY 453.7
AML#32 Female 76 At diagnosis M5 13.93 85 46, XX 2888.0
Qi et al. Journal of Hematology & Oncology 2014, 7:53 Page 4 of 12
http://www.jhoonline.org/content/7/1/53CHK1 inhibitor LY2603618 synergizes with MK-1775 to
induce apoptosis in AML cells
CTS and U937 cells were treated with MK-1775 plus the
selective CHK1 inhibitor LY2603618 for 8 h. There was
a concentration-dependent decrease in viable cells fol-
lowing LY2603618 treatment for both CTS and U937
cells (Additional file 1: Figure S2B). γH2AX levels were
increased after MK-1775 treatment, which was further
increased by the addition of LY2603618 (Figure 5A and
Additional file 1: Figure S3B). CDK1 and CDK2 phos-
phorylation was lower after MK-1775 treatment com-
pared to vehicle control and was further decreased in
the combined MK-1775 and LY2603618 treatment. MK-
1775-induced apoptosis was significantly enhanced by
the addition of LY2603618 (Figure 5B&C). MTT assaysrevealed synergistic anti-leukemic interactions from the
combined MK-1775 and LY2603618 treatment as dis-
played by the standard isobolograms (Figure 5D&E).
Similar results were obtained with primary AML patient
samples (Figure 5F-H).
Discussion
Wee1 inhibitors have primarily been used to target the
G2 cell cycle checkpoint, which is activated in response
to DNA damaging agents, and has shown promising re-
sults when combined with standard chemotherapy drugs
[10-18]. Using single agent treatment we demonstrate
that AML patient samples with t(15;17) translocation are
more sensitive to MK-1775 than non-t(15;17), suggesting
a possible treatment for patients with t(15;17) who do not
Figure 2 Diagnostic AML blasts from patients either at first diagnosis or at relapse are equally sensitive to MK-1775. Panel A: Freshly
isolated AML patient samples were purified by standard Ficoll-Hypaque density centrifugation then treated with MK-1775 for 48 h and apoptotic
events were determined by annexin V/PI staining and flow cytometry analyses. Panels B and C: Ex vivo MK-1775 (MK) sensitivity was determined
using MTT assays. The horizontal lines indicate median MK-1775 IC50s in each group of AML patient samples. Panel D: Cytarabine sensitivity
was determined using MTT assays for the HL-60 and HL-60/Ara-C cell lines. Panel E: The HL60 and HL60/Ara-C cells were treated with MK-1775
for 48 h and apoptotic events were determined by annexin V/PI staining and flow cytometry analyses. The data are presented as mean of
triplicates ± standard errors from one representative experiment. Panel F: Freshly isolated cells from patient AML#10 were purified by standard
Ficoll-Hypaque density centrifugation. AML#10, HL-60, and HL-60/Ara-C cells were treated with MK-1775 for 48 h. Whole cell lysates were
subjected to Western blotting and probed with anti-p-CDK1, -CDK1, -p-CDK2, -CDK2, -γH2AX, or -β-actin antibody.
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based therapies. The t(15;17) translocation results in re-
arrangement of the promyelocytic leukemia (PML) gene
and the retinoic acid receptor α (RARα) gene, generating
the PML/RARα fusion protein [21]. This fusion protein
acts as a strong transcriptional repressor for numerous
genes which are involved in proliferation, DNA repair, and
cell death [22,23], and thus may contribute to the elevated
MK-1775 sensitivity. We also found that newly diagnosed
and relapsed AML patient samples have similar ex vivo
MK-1775 sensitivities, as measured by MTT assays. In
addition, our studies in a cytarabine resistant cell linefurther support the preclinical development of MK-
1775 for the treatment of relapsed AML.
In our study, we demonstrate that MK-1775 treatment
results in increased phosphorylation of CHK1 and
H2AX, in agreement with Chaudhuri et al.’s report [13].
Furthermore, increased phosphorylation of both CHK1
and H2AX is dependent on CDK activity. Inhibition of
CHK1 in combination with MK-1775 resulted in syner-
gistic anti-leukemic activities in both AML cell lines and
primary patient samples. Although combined Wee1 and
CHK1 inhibition has been reported in various cancer
types [24-26], including AML [13], our study confirmed
Figure 3 (See legend on next page.)
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Figure 3 MK-1775 treatment abrogates the G2/M cell cycle checkpoint. CTS cells (Panels A and B) or U937 cells (Panels C and D) were
treated with 500 nM MK-1775 for up to 48 h. Samples were taken at the indicated time points and fixed with ethanol for PI staining and cell cycle
analysis (Panels A and C). Whole cell lysates were subjected to Western blotting and probed with anti-p-CDK1, -CDK1, -p-CDK2, -CDK2, -CHK1,
-pCHK1, -p-cdc25c, -γH2AX, or -β-actin antibody (Panels B and D).
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inhibitor, LY2603618, than has been previously reported
(MK-8776, PF-00477736, AR458323) and found similar
synergistic anti-leukemic activity. Thus, adding further
evidence for the clinical efficacy of combined Wee1 and
CHK1 inhibition for the treatment of AML.
Based on our own results and those previously reported,
we propose a mechanism for the cooperative anti-leukemic
activity of MK-1775 and LY2603618 in Figure 6. MK-1775
inhibits Wee1, inhibiting phosphorylation of CDK1/2, thus
allowing CDK1/CDK2 to remain active. Overactive CDK1/
2 eventually leads to DNA DSBs triggering activation of
ATM/ATR and CHK1. Activated CHK1 phosphorylates
CDC25s, leading to decreased removal of the inhibitory
phosphorylation on CDK1/2, in turn limiting the amount
of active CDK1/2, arresting the cell cycle to allow for ad-
equate DNA damage repair. The addition of LY2603618
inhibits the inhibitory phosphorylation of CDC25s, accord-
ingly maintaining their phosphatase activity, which main-
tains active CDK1/2 pools, perpetuating the DNA damage
induced by MK-1775 treatment and eventually resulting in
enhanced apoptosis.
In summary, our study demonstrates that MK-1775 has
potential as an anti-leukemic drug in the treatment of
AML. Particularly, our patient sample data supports the in-
vestigation of MK-1775 in relapsed AML, as they had simi-
lar sensitivities as newly diagnosed cases. In addition, AML
cases with t(15;17) translocation were significantly more
sensitive to MK-1775 treatment, suggesting a possible role
for patients who do not respond to all-trans retinoic acid
and/or arsenic trioxide-based therapies. We also demon-
strate that MK-1775 in combination with cytarabine results
in synergistic anti-leukemic activity in AML cell lines and
patient samples (Additional file 1: Figure S4). Lastly, our
results highlight CHK1 activation as a potential mechan-
ism of resistance to MK-1775 treatment, thus supports
the development of combination therapies.
Materials and methods
Drugs
MK-1775 (MK), Roscovitine (Rosc), and LY2603618 (LY)
were purchased from Selleck Chemicals (Houston, TX,
USA). Cytarabine (ara-C) was purchased from Sigma-
Aldrich (St. Louis, MO, USA).
Cell culture
The THP-1, MV4-11, U937, HL-60 cell lines were pur-
chased from the American Type Culture Collection(Manassas, VA, USA). The OCI-AML3 cell line was
purchased from the German Collection of Microorgan-
isms and Cell Cultures (DSMZ, Braunschweig, Germany).
MOLM-13 cells were purchased from AddexBio (San
Diego, CA, USA). The CTS cell line was a gift from Dr. A
Fuse from the National Institute of Infectious Diseases,
Tokyo, Japan. The cell lines were cultured in RPMI 1640
(except OCI-AML3, which was cultured in alpha-MEM)
with 10-15% fetal bovine serum (Hyclone, Logan, UT,
USA), 2 mM L-glutamine, 100 U/ml penicillin and 100 μg/
ml streptomycin. All cells were cultured in a 37°C humidi-
fied atmosphere containing 5% CO2/95% air.
AML blast samples obtained either at diagnosis or at
relapse were purified by standard Ficoll-Hypaque density
centrifugation, then cultured in RPMI 1640 with 20%
fetal bovine serum supplemented with ITS solution
(Sigma-Aldrich) and 20% supernatant of the 5637 bladder
cancer cell line [as a source of granulocyte-macrophage
colony-stimulating factor [27,28]].
HL-60 cytarabine resistant cells (designated HL-60/
Ara-C) were generated by stepwise selection of HL-60
cells in the presence of cytarabine, until they could be
maintained in the presence of 600 nM cytarabine.
Clinical samples
Diagnostic blast samples were obtained from the First
Hospital of Jilin University. Written informed consent
was provided according to the Declaration of Helsinki.
This study was approved by the Human Ethics Commit-
tee of the First Hospital of Jilin University. Clinical sam-
ples were screened for FLT3-ITD, NPM1, C-kit, CEBPA,
IDH1, IDH2 and DNMT3A gene mutations. The samples
were also screened for the following fusion genes by real-
time RT-PCR: PML-RARα, BCR-ABL, AML1-MDS1,
MLL-AF10, MLL-AF4, MLL-ELL, SET-CAN, TLS-ERG,
NPM-RARα, E2A-PBX1, AML1-EAP, MLL-AF17, MLL-
AF6, MLL-ENL, SIL-TAL1, HOX11, PLZF-RARα, TEL-
AML1, DEK-CAN, MLL-AF1p, MLL-AF9, NPM-ALK,
TEL-ABL, EIP1L1-PDGFRA, AML1-ETO, CBFB-MYH11,
E2A-HLF, MLL-AF1q, MLL-AFX, NPM-MLF1, dupMLL,
and TEL-PDGFB.
In vitro cytotoxicity assays
In vitro cytotoxicities of the AML cells were measured
by using MTT (3-[4,5-dimethyl-thiazol-2-yl]-2,5-diphe-
nyltetrazoliumbromide, Sigma-Aldrich) assays, as previ-
ously described [29,30]. Briefly, the cells were treated
with variable concentrations of MK-1775 for 72 hours.
Figure 4 MK-1775-induced DNA damage and apoptosis are dependent on CDK activity. Panel A: U937 and CTS cell lines were treated for
8 h with the indicated concentrations of Roscovitine (Rosc) and MK-1775. Whole cell lysates were subjected to Western blotting and probed with
anti-γH2AX, -p-CHK1, -CDK1, or -β-actin antibody. Densitometry measurements, as described in the Materials and methods section, are shown
below the corresponding Western blot. Panels B and C: CTS and U937 cell lines were treated with MK-1775 and Roscovitine, alone or in combination,
for 8 h and 24 h. Apoptosis was measured by annexin V/PI staining and flow cytometry analyses. The data are presented as mean of triplicates ± standard
error from one representative experiment. ***indicates p < 0.0005. Panels D-H: Standard isobologram analyses of anti-leukemic interactions between
MK-1775 and Roscovitine in the CTS cell line (Panel D), U937 cell line (Panel E), and patient samples (Panels F-H). The IC50 values of each drug are plotted
on the axes; the solid line represents the additive effect, while the points represent the concentrations of each drug resulting in 50% inhibition of
proliferation. Points falling below the line indicate synergism whereas those above the line indicate antagonism. The data for the CTS and U937 cell lines
are presented as mean values ± standard errors from at least three independent experiments, while the data for the patient samples are presented as mean
values of duplicates from one experiment.
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Figure 5 MK-1775 and LY2603618 synergize to induce apoptosis in AML cell lines and primary patient samples. Panel A: U937 and CTS
cells were treated for 8 h. Whole cell lysates were subjected to Western blotting and probed with anti-γH2AX, -pCHK1, -p-cdc25c, -p-CDK1,
-p-CDK2, -CDK1, or -β-actin antibody. Densitometry measurements, as described in the Materials and methods section, are shown below the
corresponding Western blot. Panels B and C: CTS and U937 cells were treated with MK-1775 and LY2603618, alone or in combination, for 8 h and
24 h. Apoptotic events were determined by annexin V/PI staining and flow cytometry analyses. The data are presented as mean of triplicates ±
standard error from one representative experiment. ***indicates p < 0.0005. Panels D-H: Standard isobologram analyses of antitumor interactions
between MK-1775 and LY2603618 in the CTS cell line (Panel D), U937 cell line (Panel E), and patient samples (Panels F-H). The IC50 values of each
drug are plotted on the axes; the solid line represents the additive effect, while the points represent the concentrations of each drug resulting in 50%
inhibition of proliferation. Points falling below the line indicate synergism whereas those above the line indicate antagonism. The data for the CTS and
U937 cell lines are presented as mean values ± standard errors from at least three independent experiments, while the data for the patient samples are
presented as mean of duplicates from one experiment.
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Figure 6 Proposed mechanisms for the anti-leukemic interaction
of MK-1775 and LY2603618 in AML cells. MK-1775 inhibits Wee1,
leading to decreased inhibitory phosphorylation of CDK1/2, allowing
CDK1/CDK2 to remain active. This eventually leads to DNA DSBs which
triggers activation of ATM/ATR and activates CHK1. Active CHK1 inhibits
CDC25s leading to decreased removal of the inhibitory phosphorylation
on CDK1/2, thus limiting the amount of active CDK1/2 and the
resulting DNA damage from MK-1775 treatment. The addition of a
CHK1 inhibitor (e.g. LY2603618) would inhibit the CHK1 DNA repair
pathway, allowing for the DNA damage to accumulate and cause
apoptosis.
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cells were incubated for 4 hours at 37°C. The cells were
lysed overnight using 10% SDS in 10 mM HCL and plates
were read at 590 nm using a microplate reader. IC50
values were calculated as drug concentrations necessary
to inhibit 50% growth compared to vehicle control treated
cells. The cell line IC50 values are presented as mean
values ± standard errors from at least three independent
experiments. The IC50 values for the patient samples are
means of duplicates from one experiment, due to limited
sample. Patient samples for the combined drug treatments
were chosen based on sample availability.
Western blot analysis
Cells were lysed in the presence of protease and phosphat-
ase inhibitors (Roche Diagnostics, Indianapolis, IN, USA).
Whole cell lysates were subjected to SDS-polyacrylamide
gel electrophoresis, electrophoretically transferred onto
polyvinylidene difluoride (PVDF) membranes (Thermo
Fisher Inc., Rockford, IL, USA) and immunoblotted with
anti-p-CDK1 (Y15), -CDK1, -p-CDK2 (Y15), -CDK2,
-Wee1, -MYT1, -γH2AX, -CHK1, -p-CHK1 (S345),
-p-CDC25C (S216) (Cell Signaling Technology, Danvers,
MA, USA), or -β-actin (Sigma-Aldrich) antibody, as previ-
ously described [31,32]. Immunoreactive proteins were
visualized using the Odyssey Infrared Imaging System (Li-
Cor, Lincoln, NE, USA), as described by the manufacturer.
Western blots were repeated at least three times and one
representative blot is shown. Only one patient sample was
used for MK-1775 treatment and subsequent Western
blot analysis due to the limited amount of sample avail-
able. Densitometry measurements were made using Odys-
sey V3.0 (Li-Cor), normalized to β-actin, and then fold
change relative to no drug control was calculated.Apoptosis
AML cells were treated with MK-1775, Roscovitine,
LY2603618, or the indicated combinations and subjected
to flow cytometry analysis to determine drug-induced
apoptosis using an annexin V-fluorescein isothiocyanate
(FITC)/propidium iodide (PI) apoptosis Kit (Beckman
Coulter; Brea, CA, USA), as previously described [29,33].
Results are expressed as percent of annexin V + cells. Ex-
periments with AML cell lines were performed 3 inde-
pendent times in triplicates and data presented are from
one representative experiment, while patient sample ex-
periments were performed once in triplicates. Data are
presented as mean values ± standard errors from one rep-
resentative experiment. Due to limited sample, only three
patient samples were evaluated for MK-1775-induced
apoptosis by flow cytometry.Cell cycle progression
Cells were treated with the indicated drugs for up to
48 h. The cells were harvested and fixed with ice-cold
80% (v/v) ethanol for 24 h. The cells were pelleted, washed
with PBS, and resuspended in PBS containing 50 μg/mL
propidium iodide (PI), 0.1% Triton X-100 (v/v), and 1 μg/
mL DNase-free RNase. DNA content was determined by
flow cytometry analysis using a FACScan flow cytometer
(Becton Dickinson, San Jose, CA, USA) as previously de-
scribed [34]. Cell cycle analysis was performed using Mul-
ticycle software (Phoenix Flow Systems, Inc., San Diego,
CA, USA). Histograms were created using FlowJo v7.6.5
(Tree Star, Ashland, OR, USA).Statistical analysis
Differences in cell apoptosis between treated (individu-
ally or combined) and untreated cells were compared
using the pair-wise two-sample t-test. The p value for
the differences between MK-1775 IC50s for the groups of
patient samples was calculated using the Mann–Whitney
U test. Statistical analyses were performed with GraphPad
Prism 5.0.Additional files
Additional file 1: Figure S1. MK-1775 causes concentration-dependent
abrogation of the G2/M cell cycle checkpoint. Figure S2. Concentration-
dependent decrease in viable cells after roscovitine or LY2603618
treatment. Figure S3. Densitometry measurements for the western blot
experiments corresponding to Figures 4A and 5A. Figure S4. MK-1775
and cytarabine synergize in AML cells.
Additional file 2: Table S1. Cell cycle distribution of CTS and U937
cells following MK-1775 treatment.Competing interest
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